Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2008-01-18
2010-10-26
Ton, Thaian N (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S04400A
Reexamination Certificate
active
07820157
ABSTRACT:
A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.
REFERENCES:
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5354674 (1994-10-01), Hodgson
patent: 5512421 (1996-04-01), Burns et al.
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5643770 (1997-07-01), Mason et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5710022 (1998-01-01), Zhu et al.
patent: 5800811 (1998-09-01), Hall et al.
patent: 5821234 (1998-10-01), Dzau
patent: 5824837 (1998-10-01), Chen et al.
patent: 5985655 (1999-11-01), Anderson et al.
patent: 6004798 (1999-12-01), Anderson et al.
patent: 6864082 (2005-03-01), Hall, et al.
patent: 7347998 (2008-03-01), Hall et al.
patent: 2002/0173538 (2002-11-01), Shiao
patent: 334301 (1989-09-01), None
patent: 503225 (1996-04-01), None
patent: WO 92/06180 (1992-04-01), None
patent: WO 93/00103 (1993-01-01), None
patent: WO 93/09221 (1993-05-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/20221 (1993-10-01), None
patent: WO 93/25234 (1993-12-01), None
patent: WO 94/06920 (1994-03-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/11524 (1994-05-01), None
patent: WO 94/12626 (1994-06-01), None
patent: WO 94/27643 (1994-12-01), None
patent: WO 96/30504 (1996-03-01), None
patent: WO 96/23882 (1996-08-01), None
patent: WO 96/31602 (1996-10-01), None
patent: WO 02/18572 (2002-03-01), None
Barinaga. Step taken toward improved vectors for gene transfer. Science. 1994; 266:1326.
Behrens, et al. Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest Ophthalmol Vis Sci. 2002;43(4):968-77.
Chu, et al. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther. 1994;1(5):292-9.
Cripps, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clinical Cancer Research. 2002; 8:2188-2192.
Defer, et al. Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J. Virology. 1990; 64:3661-3673.
Galanis, et al. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 2001; 38(3):177-192.
Gautam, et al. Delivery systems for pulmonary gene therapy. Am J. respir Med. 2002; 1(1):35-46.
Gordon, et al. First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol. 2004;24(1):177-85.
Gordon, et al. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res. 2000;60(13):3343-7.
Gordon, et al. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol. 2007; 30(6):1297-307.
Gordon, et al. Lesion-targeted injectable vectors for vascular restenosis. Hum Gene Ther. 2001;12(10):1277-87.
Gordon, et al. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. Int J Oncol. 2006; 29(5):1053-64.
Gordon, et al. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther. 2001;12(2):193-204.
Guibinga, et al. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol Ther. 2004;9(1):76-84.
Hall, et al. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther. 2000;11(7):983-93.
Hall, et al. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum Gene Ther. 1997;8(18):2183-92.
Jones, et al. Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. Advanced Drug Delivery Reviews. 1998; 31:153-170.
Kasahara, et al. Tissue-specific targeting of retroviral vetors through ligand-receptor interactions. Science. 1994; 266:1373-1376.
Kozak, et al. Ping-pong amplification of a retroviral vector achieves high-level gene expression: human growth hormone production. J. Virol. 1990; 64(7):3500-3508.
Lenz, et al. Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver. Human Gene therapy. 2002; 12:1515-1537.
Marshall, et al. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 2004; 4:268-274.
Neda, et al. Chemical modification of an ecotropic mruine leukemia virus results in redirection of its target cell specificity. J. Biol. Chem. 1991; 266(22):14143-14146.
Oza, et al. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecological Oncology. 2003; 89:129-133.
Salmons, et al. Targeting of retroviral vectors for gene therapy. Human Gene Therapy. 1993; 4:129-141.
Scanlon, K. J. Anti-genes: siRNA, ribozymes and antisense. Curr Pharm Biotech. 2004; 5:415-420.
Skotzko, et al. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Research. 1995; 55:5493-5498.
Soneoka, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995;23(4):628-33.
Song, et al. Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring. Hum Gene Ther. 2003;14(3):306-9.
Tolcher, et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clinical Cancer Research. 2002; 8: 2530-2535.
Tomasoni, et al. Gene therapy: how to target the kidney. Promises and pitfalls. current Gene Therapy. 2004; 4(1):115-122.
Valsesia-Wittmann, et al. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J. Virol. 1996; 70(3): 2059-2064.
Williams, et al. Identification of a novel cyclin-like protein in human tumor cells. Journal of Biological Chemistry. 1993; 268:8871-8880.
Wong, et al. Bone Marrow Transplantation Experimentation. Abstract 1001. Dec. 1994.
Xie, et al. Elements within the first 17 amino acids of human osteonectin are responsible for binding to type V collagen. J. Biol. Chem. 1996; 271(14):8121-8125.
Xu, et al. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med. 2001;8(1):19-30.
Yang, X. Imaging of vascular gene therapy. Radiology. 2003; 228:36-49.
Smirnov, et al. Carrier-directed targeting of liposomes and erythrocytes to denuded areas of vessel wall. Proc Natl Acad Sci U S A. Sep. 1986;83(17):6603-7.
Takagi, et al. A collagen/gelatin-binding decapeptide derived from bovine propolypeptide of von Willebrand factor. Biochemistry. Sep, 15, 1992;31(36):8530-4.
Cosset, et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain J Virol. Oct. 1995;69(10):6314-22.
Ito, et al. Quaternary structure-dependen
Gordon Erlinda Maria
Hall Frederick L.
Noble Marcia S
Ton Thaian N
University of Southern California
Wilson Sonsini Goodrich & Rosati
LandOfFree
Transgene delivering retrovirus targeting collagen exposed... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgene delivering retrovirus targeting collagen exposed..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgene delivering retrovirus targeting collagen exposed... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4234801